TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy and Safety of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe COPD
Brief Summary: To demonstrate the non-inferiority of QVA149 110/50 µg o.d. to fluticasone/salmeterol 500/50 µg b.i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours 15 min and 23 hours 45 min post QVA149 dose) following 26 weeks of treatment in patients with moderate to severe COPD


Options:
A: Arm Label: Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium bromide/Vilanterol, Drug: Placebo ACCUHALER/DISKUS | Arm Label: Fluticasone propionate/Salmeterol + placebo NDPI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/Salmeterol, Drug: Placebo NDPI | Intervention Type: DRUG; Name: Umeclidinium bromide/Vilanterol; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Placebo ACCUHALER/DISKUS; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Fluticasone propionate/Salmeterol; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI | Intervention Type: DRUG; Name: Placebo NDPI; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI
B: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone/salmeterol, Drug: Placebo to QVA149 | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to QVA149; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149
C: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
D: Intervention Type: DRUG; Name: Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Magnesium Oxide Monohydrate for Nocturnal Leg Cramps (MgNLC); a Prospective, Randomized, Double Blind, Placebo Controlled Clinical Trial.
Brief Summary: Nocturnal leg cramps (NLC) are painful, involuntary contractions of muscles occurring at rest, mostly at night. A Cochrane review on leg cramps in pregnancy showed some potential benefits in trials of magnesium. This is a single center, prospective, randomized, double blind, placebo controlled clinical trial that aims to investigate the effect of treatment with Magnox 520® (un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg++) on frequency and severity of NLC, quality of sleep and quality of life. Hypothesis: Magnox 520® may reduce the number and severity of NLC; an improvement in the quality of life and quality of sleep may ensue.


Options:
A: Arm Label: Physical training - No encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - No encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Arm Label: Physical training - Early encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - Early encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training - Early encephalopathy, Physical training - No encephalopathy | Intervention Type: OTHER; Name: Diet intervention; Assigned to Arm(s): Control - Early encephalopathy, Control - No encephalopathy, Physical training - Early encephalopathy, Physical training - No encephalopathy
B: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Other: Fitness exercise program | Intervention Type: OTHER; Name: Fitness exercise program; Assigned to Arm(s): exercise
C: Arm Label: MAGNOX 520®; Type: EXPERIMENTAL; Interventions: Drug: MAGNOX 520® | Arm Label: Similarly looking placebo.; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MAGNOX 520®; Assigned to Arm(s): MAGNOX 520® | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Similarly looking placebo.
D: Arm Label: Transdermal Magnesium; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Magnesium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Transdermal Magnesium; Assigned to Arm(s): Transdermal Magnesium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)
Brief Summary: The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg / day) reduces the risk of cardiovascular disease in patients with chronic kidney disease (stage 3 or 4).


Options:
A: Arm Label: Experimental treatment strategy; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor, Drug: Acetylsalicylic Acid | Arm Label: Reference treatment strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ticagrelor, Drug: Acetylsalicylic Acid, Drug: Clopidogrel | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Experimental treatment strategy, Reference treatment strategy | Intervention Type: DRUG; Name: Acetylsalicylic Acid; Assigned to Arm(s): Experimental treatment strategy, Reference treatment strategy | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Reference treatment strategy
B: Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: No aspirin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: No aspirin; Assigned to Arm(s): 2
D: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: standard medication; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Assess Mechanism Of Action (Moa) Of Cp-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (Bid) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
C: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: 80 mg ixekizumab; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Assess Mechanism Of Action (Moa) Of Cp-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (Bid) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
B: Arm Label: AIN457 150 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Intervention Type: DRUG; Name: secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: placebo to secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo, placebo
C: Arm Label: Adalimumab (Humira); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab (Humira) | Arm Label: Placebo Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Injection | Arm Label: NB-UVB phototherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: NB-UVB phototherapy | Intervention Type: DRUG; Name: Adalimumab (Humira); Assigned to Arm(s): Adalimumab (Humira) | Intervention Type: DRUG; Name: Placebo Injection; Assigned to Arm(s): Placebo Injection | Intervention Type: OTHER; Name: NB-UVB phototherapy; Assigned to Arm(s): NB-UVB phototherapy
D: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo Controlled Trial of Varenicline for Smoking Among Those With HIV/AIDS
Brief Summary: Among people diagnosed with HIV/AIDS, the widespread use of highly active antiretroviral therapy (HAART) has greatly improved survival rates and changed the leading causes of death, from AIDS-related diseases to cardiovascular disease and lung cancer. Rates of tobacco use among individuals with HIV/AIDS are very high and varenicline may be particularly efficacious for treating nicotine dependence among individuals with HIV/AIDS. Through this trial, 310 smokers with HIV/AIDS will be randomized to varenicline plus 9 weeks of smoking cessation counseling or placebo plus 9 weeks of smoking cessation counseling. The investigators hypothesize that 1) varenicline and counseling will significantly increase end-of-treatment (week 12) and 24-week biochemically-confirmed abstinence, versus placebo and counseling; 2) quality of life will be rated higher in the varenicline and counseling group versus the placebo and counseling group, and there will be no significant differences between treatment arms in terms of the frequency of severe varenicline-related side effects; and 3) improved affect and reduced cognitive impairment will mediate the effect of varenicline therapy on quit rates.


Options:
A: Arm Label: Champix; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: Long & Combination patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch combined with gum or inhaler | Arm Label: Standard patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix | Intervention Type: DRUG; Name: Transdermal Nicoderm patch combined with gum or inhaler; Assigned to Arm(s): Long & Combination patch treatment | Intervention Type: DRUG; Name: Transdermal Nicoderm patch; Assigned to Arm(s): Standard patch treatment
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Placebo, Varenicline
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study
Brief Summary: A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.


Options:
A: Arm Label: Low-fluence PDT with Verteporfin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Verteporfin | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: Verteporfin; Assigned to Arm(s): Low-fluence PDT with Verteporfin | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): Ranibizumab
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: subthreshold micropulselaser, Drug: bevacizumab | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: subthreshold micropulselaser | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: subthreshold micropulselaser; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 1
C: Arm Label: Half-dose photodynamic therapy (PDT); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Half-dose photodynamic therapy (PDT) | Arm Label: Micropulse laser (ML) treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Micropulse laser (ML) treatment | Intervention Type: PROCEDURE; Name: Half-dose photodynamic therapy (PDT); Assigned to Arm(s): Half-dose photodynamic therapy (PDT) | Intervention Type: PROCEDURE; Name: Micropulse laser (ML) treatment; Assigned to Arm(s): Micropulse laser (ML) treatment
D: Arm Label: Intravitreal Aflibercept Injection (x4); Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Aflibercept Injection | Arm Label: Intravitreal Aflibercept Injection (x6); Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Aflibercept Injection | Intervention Type: DRUG; Name: Intravitreal Aflibercept Injection; Assigned to Arm(s): Intravitreal Aflibercept Injection (x4), Intravitreal Aflibercept Injection (x6)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Brief Summary: The purpose of this Randomized, Double-blind, Multicenter, Two-period Crossover Study is to Assess the Efficacy and Tolerability of Burlulipase (NM-BL) in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis


Options:
A: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)
B: Arm Label: Burlulipase; Type: EXPERIMENTAL; Interventions: Drug: Burlulipase | Arm Label: Placebo (Caramel in sterile water); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Caramel in sterile water) | Intervention Type: DRUG; Name: Burlulipase; Assigned to Arm(s): Burlulipase | Intervention Type: DRUG; Name: Placebo (Caramel in sterile water); Assigned to Arm(s): Placebo (Caramel in sterile water)
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: EUR-1008 then Kreon; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Arm Label: Kreon then EUR-1008; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 25,000 Units, Drug: Kreon 25,000 Units | Intervention Type: DRUG; Name: EUR-1008 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008 | Intervention Type: DRUG; Name: Kreon 25,000 Units; Assigned to Arm(s): EUR-1008 then Kreon, Kreon then EUR-1008

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Brief Summary: The purpose of this Randomized, Double-blind, Multicenter, Two-period Crossover Study is to Assess the Efficacy and Tolerability of Burlulipase (NM-BL) in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pancrelipase Delayed Release | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pancrelipase Delayed Release; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): B
B: Arm Label: Cystic Fibrosis in 1st 3 months of life; Type: N/A; Interventions: N/A
C: Arm Label: Burlulipase; Type: EXPERIMENTAL; Interventions: Drug: Burlulipase | Arm Label: Placebo (Caramel in sterile water); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Caramel in sterile water) | Intervention Type: DRUG; Name: Burlulipase; Assigned to Arm(s): Burlulipase | Intervention Type: DRUG; Name: Placebo (Caramel in sterile water); Assigned to Arm(s): Placebo (Caramel in sterile water)
D: Arm Label: Patients with CF; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Arm Label: Age-matched healthy controls; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Intervention Type: DIAGNOSTIC_TEST; Name: Questionnaire Patient Reported Outcome Measure (PROM); Assigned to Arm(s): Age-matched healthy controls, Patients with CF

Answer: C